NASDAQ:NVCN Neovasc (NVCN) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$29.43▼$30.0750-Day Range$29.03▼$30.0352-Week Range$4.59▼$30.07Volume45,400 shsAverage Volume56,993 shsMarket Capitalization$82.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Neovasc (NASDAQ:NVCN) StockNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.Read More Receive NVCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCN Stock News HeadlinesMay 7, 2023 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Now Covered by StockNews.comApril 28, 2023 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Coverage Initiated by Analysts at StockNews.comJune 1, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. April 20, 2023 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Receives New Coverage from Analysts at StockNews.comApril 15, 2023 | theglobeandmail.comClosing Bell: Neovasc Inc down on Tuesday (NVCN)April 12, 2023 | americanbankingnews.comNeovasc (NASDAQ:NVCN) Now Covered by Analysts at StockNews.comApril 11, 2023 | theglobeandmail.comClosing Bell: Neovasc Inc up on Monday (NVCN)March 31, 2023 | finance.yahoo.comNeovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate UpdateJune 1, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...March 21, 2023 | americanbankingnews.comHead to Head Analysis: Neovasc (NASDAQ:NVCN) versus Meihua International Medical Technologies (NASDAQ:MHUA)March 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Neovasc (NASDAQ:NVCN)March 9, 2023 | finance.yahoo.comNeovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last yearMarch 6, 2023 | finance.yahoo.comNeovasc Shareholders Approve Acquisition by Shockwave MedicalFebruary 1, 2023 | finance.yahoo.comNeovasc Announces German Reimbursement RenewalJanuary 11, 2023 | finance.yahoo.comNeovasc (NVCN) is on the Move, Here's Why the Trend Could be SustainableDecember 26, 2022 | finance.yahoo.comRecent Price Trend in Neovasc (NVCN) is Your Friend, Here's WhyDecember 21, 2022 | finance.yahoo.com3 Medical Instruments Stocks on Recovery Path After Dismal 2022November 28, 2022 | finance.yahoo.comNeovasc Announces Progress on COSIRA-II Clinical TrialNovember 17, 2022 | finance.yahoo.comNeovasc Third Quarter 2022 Earnings: Misses ExpectationsNovember 10, 2022 | finance.yahoo.comNeovasc Announces Third Quarter Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comNeovasc to Report Third Quarter Financial Results on November 10, 2022September 30, 2022 | proactiveinvestors.comNeovasc uses conference to announce positive interim clinical data from Neovasc Reducer use - Proactive Investors USASeptember 20, 2022 | streetinsider.comForm 6-K NEOVASC INC For: Sep 20 - StreetInsider.comSeptember 20, 2022 | seekingalpha.comNeovasc puts further development of its Tiara transcatheter treatment on hold - Seeking AlphaSeptember 20, 2022 | globenewswire.comNeovasc Provides Corporate Update Following Clinical Data Release - GlobeNewswireSeptember 17, 2022 | finance.yahoo.comNeovasc to Participate in LSI Europe 2022 Emerging MedTech Summit - Yahoo FinanceSeptember 16, 2022 | globenewswire.comNeovasc to Participate in LSI Europe 2022 Emerging MedTech Summit - GlobeNewswireSee More Headlines Receive NVCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCN Company Calendar Last Earnings3/31/2023Today5/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCN CUSIPN/A CIK1399708 Webwww.neovasc.com Phone(604) 270-4344Fax604-270-4384Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-1,082.92% Pretax Margin-1,082.26% Return on Equity-127.25% Return on Assets-80.31% Debt Debt-to-Equity Ratio0.80 Current Ratio2.96 Quick Ratio2.85 Sales & Book Value Annual Sales$3.81 million Price / Sales21.60 Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book5.20Miscellaneous Outstanding Shares2,740,000Free FloatN/AMarket Cap$82.28 million OptionableNot Optionable Beta1.70 Key ExecutivesFredericus Antonius ColenPresident, Chief Executive Officer & DirectorBill LittleChief Operating OfficerChristopher ClarkChief Financial Officer & SecretarySarah GallagherVice President-Clinical AffairsShmuel BanaiMedical DirectorKey CompetitorsLyra TherapeuticsNASDAQ:LYRADelcath SystemsNASDAQ:DCTHProSomnusNASDAQ:OSANeuroneticsNASDAQ:STIMAkiliNASDAQ:AKLIView All CompetitorsInstitutional OwnershipAnqa Management LLCBought 12,047 shares on 5/17/2023Ownership: 0.440%Black Maple Capital Management LPBought 107,685 shares on 5/16/2023Ownership: 3.930%Jane Street Group LLCBought 11,464 shares on 5/16/2023Ownership: 0.418%Sio Capital Management LLCBought 22,537 shares on 5/15/2023Ownership: 0.823%Quinn Opportunity Partners LLCBought 20,000 shares on 5/15/2023Ownership: 0.730%View All Institutional Transactions NVCN Stock - Frequently Asked Questions Should I buy or sell Neovasc stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVCN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCN, but not buy additional shares or sell existing shares. View NVCN analyst ratings or view top-rated stocks. How were Neovasc's earnings last quarter? Neovasc Inc. (NASDAQ:NVCN) announced its earnings results on Friday, March, 31st. The medical equipment provider reported ($5.04) earnings per share for the quarter, missing the consensus estimate of ($1.93) by $3.11. The medical equipment provider had revenue of $1.45 million for the quarter, compared to analyst estimates of $0.90 million. Neovasc had a negative trailing twelve-month return on equity of 127.25% and a negative net margin of 1,082.92%. When did Neovasc's stock split? Neovasc's stock reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Neovasc own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), Amarin (AMRN). What is Neovasc's stock symbol? Neovasc trades on the NASDAQ under the ticker symbol "NVCN." Who are Neovasc's major shareholders? Neovasc's stock is owned by many different retail and institutional investors. Top institutional shareholders include Black Maple Capital Management LP (3.93%), Yakira Capital Management Inc. (1.37%), MMCAP International Inc. SPC (1.01%), Sio Capital Management LLC (0.82%), Quinn Opportunity Partners LLC (0.73%) and Renaissance Technologies LLC (0.64%). What is Neovasc's stock price today? One share of NVCN stock can currently be purchased for approximately $30.03. How much money does Neovasc make? Neovasc (NASDAQ:NVCN) has a market capitalization of $82.28 million and generates $3.81 million in revenue each year. The medical equipment provider earns $-41,200,000.00 in net income (profit) each year or ($15.08) on an earnings per share basis. How can I contact Neovasc? Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for the company is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384. This page (NASDAQ:NVCN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neovasc Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.